Invivyd, Inc. Files 8-K: Officer/Director Changes & More
Ticker: IVVD · Form: 8-K · Filed: Sep 24, 2025 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | 8-K |
| Filed Date | Sep 24, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $40,000, $5,000, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, corporate-governance, filing
TL;DR
Invivyd 8-K: Leadership shakeup, new officers appointed, and compensation details filed.
AI Summary
Invivyd, Inc. filed an 8-K on September 24, 2025, reporting on events as of September 22, 2025. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. It also includes Regulation FD disclosures, other events, and financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in Invivyd's leadership and governance structure, which could impact the company's strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors or officers, especially if numerous or unexpected, can signal internal challenges or strategic realignments that may affect future performance.
Key Players & Entities
- Invivyd, Inc. (company) — Registrant
- Adagio Therapeutics, Inc. (company) — Former Company Name
FAQ
What specific officers or directors departed from Invivyd, Inc. as of September 22, 2025?
The filing indicates the 'Departure of Directors or Certain Officers' as an item reported, but does not list specific names in the provided text.
Were any new directors or officers elected or appointed to Invivyd, Inc. on or around September 22, 2025?
Yes, the filing explicitly lists 'Election of Directors' and 'Appointment of Certain Officers' as reported items.
Does the 8-K filing detail any new compensatory arrangements for Invivyd, Inc. officers?
Yes, 'Compensatory Arrangements of Certain Officers' is listed as a reported item in the filing.
What is the primary business of Invivyd, Inc. according to the filing?
Invivyd, Inc. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code 2836.
When was Invivyd, Inc. formerly known as Adagio Therapeutics, Inc. and when did the name change occur?
The former company name was Adagio Therapeutics, Inc., and the date of the name change was November 12, 2020.
Filing Stats: 1,104 words · 4 min read · ~4 pages · Grade level 10.6 · Accepted 2025-09-24 16:45:16
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share IVVD The Nasdaq Stock Mar
- $40,000 — will receive an annual cash retainer of $40,000 for his Board service. Dr. Bolno will r
- $5,000 — e an additional annual cash retainer of $5,000 for his service on the Compensation Com
- $1.00 — e the Common Stock had closed below the $1.00 per share minimum for 30 consecutive bu
Filing Documents
- ivvd-20250922.htm (8-K) — 65KB
- ivvd-ex99_1.htm (EX-99.1) — 14KB
- img59752938_0.jpg (GRAPHIC) — 84KB
- 0001193125-25-215541.txt ( ) — 314KB
- ivvd-20250922.xsd (EX-101.SCH) — 31KB
- ivvd-20250922_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 24, 2025, the Company issued a press release announcing Dr. Bolno's appointment to the Board. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 7.01.
01 Other Events
Item 8.01 Other Events. On September 22, 2025, the Company received a letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement") for continued listing on The Nasdaq Global Market. As previously disclosed, on April 21, 2025, the Company received a letter from Nasdaq, notifying the Company that it was not in compliance with the Minimum Bid Price Requirement because the Common Stock had closed below the $1.00 per share minimum for 30 consecutive business days. To regain compliance with the Minimum Bid Price Requirement, the Common Stock was required to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. In its letter dated September 22, 2025, Nasdaq indicated the Company has regained compliance with the Minimum Bid Price Requirement, and the matter is now closed.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated September 24, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: September 24, 2025 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary